文献速递艾滋病与性传播感染

多替拉韦联合拉米夫定维持HIV病毒抑制的96周疗效:ART-PRO试验

Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

96周时90.2%的参与者HIV-1 RNA<50拷贝/mL,无病毒学失败,尽管部分人存在 archived 少数耐药突变。

要点

  • 多替拉韦联合拉米夫定在96周内维持病毒学抑制,包括有历史拉米夫定耐药者。
  • 基线前病毒DNA NGS检测到少数拉米夫定耐药突变常见,但未导致治疗失败。
  • 研究期间无因不良事件停药,仅1例因撤回知情同意停药。

核心结论

  • 在多替拉韦联合拉米夫定治疗96周时,即使存在历史拉米夫定耐药和持续存档的少数耐药突变,仍维持病毒学抑制且无病毒学失败。

主要发现

  • 96周时90.2%的参与者达到HIV-1 RNA<50拷贝/mL的疗效终点。
  • 第48至96周期间,1例因撤回知情同意停药,无因不良事件停药。
  • 2例出现短暂病毒反弹,均在多替拉韦联合拉米夫定治疗下重新抑制。
  • 至96周无病毒学失败。
  • 基线前病毒DNA NGS检测显示,有历史拉米夫定耐药者中71.4%(15/21)检出超过5%阈值的拉米夫定耐药突变(M184V/I和/或K65R/E/N),无历史耐药者中为15%(3/20)。

临床怎么用

  • 对于已抑制的HIV感染者,多替拉韦联合拉米夫定可作为维持治疗方案,包括有历史拉米夫定耐药但基线群体测序未检出耐药者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the ART-PRO pilot trial there were no virological failures through 48 weeks of treatment with dolutegravir plus lamivudine in suppressed individuals with and without archived lamivudine resistance-associated mutations (RAMs) detected through next-generation sequencing (NGS) but without evidence of lamivudine RAMs in baseline proviral DNA population sequencing. OBJECTIVES: To present 96 week results from ART-PRO. METHODS: Open-label, single-arm pilot trial. At baseline, all participants switched to dolutegravir plus lamivudine. Participants were excluded if proviral DNA population genotyping detected lamivudine RAMs. To detect resistance minority variants, proviral DNA NGS was retrospectively performed from baseline samples. For this analysis the efficacy endpoint was the proportion of participants with <50 HIV-1 RNA copies/mL at week 96. Safety and tolerability outcomes were incidence of adverse events and treatment discontinuations. RESULTS: Forty-one participants were included, 21 with lamivudine RAMs in historical plasma RNA genotypes. Baseline proviral DNA NGS detected lamivudine RAMs (M184V/I and/or K65R/E/N) above a 5% threshold in 71.4% (15/21) and 15% (3/20) of participants with and without history of lamivudine resistance, respectively. At 96 weeks, 90.2% of participants achieved the efficacy endpoint. Between week 48 and 96 there was one discontinuation due to consent withdrawal and no discontinuations related to adverse events. Two participants had a transient viral rebound, both re-suppressed on dolutegravir plus lamivudine. Through week 96, there were no virological failures. CONCLUSIONS: In this pilot trial, dolutegravir plus lamivudine maintained virological suppression at 96 weeks despite historical lamivudine resistance and persisting archived minority lamivudine RAMs.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Rial-Crestelo D, de Miguel R, Montejano R, et al. Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study. J Antimicrob Chemother. 2021. PMID: 33200210. doi:10.1093/jac/dkaa479

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。